NDC product
ALYFTREK
NDC 51167-121 · Vertex Pharmaceuticals Incorporated
Key facts
| Product NDC | 51167-121 |
|---|---|
| Proprietary name | ALYFTREK |
| Nonproprietary name | vanzacaftor, tezacaftor, and deutivacaftor |
| Substances | VANZACAFTOR, TEZACAFTOR, DEUTIVACAFTOR |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Vertex Pharmaceuticals Incorporated |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA218730 |
| Pharmacologic classes | Breast Cancer Resistance Protein Inhibitors [MoA], Chloride Channel Activation Potentiators [MoA], Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC], Cytochrome P450 2C9 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA] |
| Marketing start | Dec 20, 2024 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: